Whole Genome Sequencing for Brain Tumors

Genomic information has been used to identify genetic diseases, find mutations that drive brain tumor development and track brain tumor outbreaks. Whole-genome sequencing (WGS) provides single-base resolution of the entire genome. In a single run, structural variants (SV) can be identified for large segments of the genome and also include variants that are small enough to be potentially missed. Potentially pathogenic variants can be identified, thus allowing researchers to target further studies of gene expression and regulatory mechanisms.

WGS services we offer on brain tumors

The ability of WGS to provide a comprehensive view of the entire genome and the ability of Alfa Cytology to handle large sample data make WGS a powerful tool for basic brain tumor research. We can provide WGS services for brain tumor research areas, which can help our clients to obtain more information about brain tumor diseases.

• In addition to obtaining information on gene expression regions, we can also obtain information on introns and intergenic regions.
• WGS can be performed on different brain tumor individuals or patient groups to perform bioinformatic analysis at the individual or group level.
• Various types of variants such as single nucleotide variation (SNV), copy number alteration (CNV), insertion and deletion (InDel), and SV can be comprehensively mined from the genome. It provides important information for screening the causative and susceptibility genes of brain tumors, studying the pathogenesis and genetic mechanism, and exploring the molecular targets related to brain tumors.

General services flow

Bioinformatics analysis projects we can provide

Sample types: fresh frozen tissue, FFPE samples, blood samples, etc.

With WGS, Alfa Cytology can provide clients with a comprehensive view of the various alterations in a given brain tumor sample, including variants contributed by surrounding normal tissue and tumor clonality, by comparing DNA from a brain tumor and normal samples. Our WGS service also reveals the molecular abnormalities that drive brain tumor development, revealing targets that may help develop new therapies that target only cancer cells while not damaging healthy cells. Please feel free to contact us to learn which genes are mutated and drive the development of brain tumors so that you can select therapies that are best suited to attack specific molecules of cancer and thus provide more effective treatment options to your patients.